CRESCENT BIOPHARMA, INC. Financing Cash Flow
CRESCENT BIOPHARMA, INC. (CBIO) reported Financing Cash Flow of -$6.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $136.00K, a 99.91% decline year-over-year.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$6.95M.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $178.86M, a 335.87% increase year-over-year.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.25M.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2025 was $322.98M, a 5983301.26% increase from fiscal 2024.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2024 was $5.40K, a 99.98% decline from fiscal 2023.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2023 was $28.82M, a 593.30% increase from fiscal 2022.
- CRESCENT BIOPHARMA, INC. net cash provided by (used in) financing activities for fiscal 2022 was $4.16M, a 61.23% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 0 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 130 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$6.81M 10-Q · filed 2026-07-30 | $172.05M derived: sum of 3 quarters · filed 2026-07-30 | $170.80M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | -$6.95M 10-Q · filed 2026-04-29 | $171.91M derived: sum of 2 quarters · filed 2026-04-29 | $170.66M derived: sum of 3 quarters · filed 2026-04-29 | $317.52M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | $178.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $177.61M derived: sum of 2 quarters · filed 2026-02-26 | $324.47M derived: sum of 3 quarters · filed 2026-07-30 | $322.98M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $145.61M derived: sum of 2 quarters · filed 2026-07-30 | $144.12M 10-Q · filed 2025-11-06 | $185.16M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $146.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $145.38M 10-Q · filed 2026-07-30 | $186.41M derived: sum of 3 quarters · filed 2026-07-30 | $186.41M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | -$1.49M 10-Q · filed 2026-04-29 | $39.55M derived: sum of 2 quarters · filed 2026-04-29 | $39.55M derived: sum of 3 quarters · filed 2026-04-29 | $39.55M derived: sum of 4 quarters · filed 2026-04-29 | ||
| 2024-12-31 | $41.03M 10-K · filed 2026-02-26 | $41.03M derived: sum of 2 quarters · filed 2026-02-26 | $41.04M derived: sum of 3 quarters · filed 2026-02-26 | $5.40K 10-K · filed 2025-02-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $500.00 derived: sum of 2 quarters · filed 2024-11-13 | $5.40K 10-Q · filed 2024-11-13 | $6.40K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $500.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.40K 10-Q · filed 2024-08-08 | $6.40K derived: sum of 3 quarters · filed 2025-05-14 | $68.01K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-03-31 | $4.90K 10-Q · filed 2025-05-14 | $5.90K derived: sum of 2 quarters · filed 2025-05-14 | $67.51K derived: sum of 3 quarters · filed 2025-05-14 | $87.63K derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $999.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $62.62K derived: sum of 2 quarters · filed 2025-02-13 | $82.73K derived: sum of 3 quarters · filed 2025-02-13 | $28.82M 10-K · filed 2025-02-13 | ||
| 2023-09-30 | $61.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $81.73K derived: sum of 2 quarters · filed 2024-11-13 | $28.82M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $20.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $28.76M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $28.74M 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $4.16M 10-K · filed 2024-03-27 | |||||
| 2021-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.16M derived: sum of 2 quarters · filed 2024-03-27 | $1.16M derived: sum of 3 quarters · filed 2024-03-27 | $10.72M 10-K · filed 2024-03-27 | ||
| 2021-09-30 | $20.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $20.79K derived: sum of 2 quarters · filed 2022-11-09 | $9.58M 10-Q · filed 2022-11-09 | $13.47M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $9.56M 10-Q · filed 2022-08-03 | $13.45M derived: sum of 3 quarters · filed 2023-03-29 | $18.00M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-03-31 | $9.56M 10-Q · filed 2022-04-28 | $13.45M derived: sum of 2 quarters · filed 2023-03-29 | $18.00M derived: sum of 3 quarters · filed 2023-03-29 | $27.58M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2020-12-31 | $3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $8.43M derived: sum of 2 quarters · filed 2023-03-29 | $18.01M derived: sum of 3 quarters · filed 2023-03-29 | $18.14M 10-K · filed 2023-03-29 | ||
| 2020-09-30 | $4.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $14.13M derived: sum of 2 quarters · filed 2021-11-02 | $14.26M 10-Q · filed 2021-11-02 | $14.37M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2020-06-30 | $9.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $9.71M 10-Q · filed 2021-08-05 | $9.83M derived: sum of 3 quarters · filed 2022-03-03 | $10.02M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2020-03-31 | $129.97K 10-Q · filed 2021-05-03 | $249.79K derived: sum of 2 quarters · filed 2022-03-03 | $436.56K derived: sum of 3 quarters · filed 2022-03-03 | $512.33K derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2019-12-31 | $119.82K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $306.59K derived: sum of 2 quarters · filed 2022-03-03 | $382.36K derived: sum of 3 quarters · filed 2022-03-03 | $412.91K 10-K · filed 2022-03-03 | ||
| 2019-09-30 | $186.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $262.54K derived: sum of 2 quarters · filed 2020-11-06 | $293.09K 10-Q · filed 2020-11-06 | $419.06K derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-06-30 | $75.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $106.32K 10-Q · filed 2020-07-31 | $232.29K derived: sum of 3 quarters · filed 2021-03-02 | $737.06K derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-03-31 | $30.55K 10-Q · filed 2020-05-01 | $156.52K derived: sum of 2 quarters · filed 2021-03-02 | $661.29K derived: sum of 3 quarters · filed 2021-03-02 | $547.37K derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2018-12-31 | $125.97K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $630.74K derived: sum of 2 quarters · filed 2021-03-02 | $516.82K derived: sum of 3 quarters · filed 2021-03-02 | $129.45M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $504.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $390.85K derived: sum of 2 quarters · filed 2019-11-07 | $129.32M 10-Q · filed 2019-11-07 | $148.78M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2018-06-30 | -$113.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $128.82M 10-Q · filed 2019-08-01 | $148.27M derived: sum of 3 quarters · filed 2020-02-28 | $148.26M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2018-03-31 | $128.93M 10-Q · filed 2019-05-02 | $148.39M derived: sum of 2 quarters · filed 2020-02-28 | $148.38M derived: sum of 3 quarters · filed 2020-02-28 | $239.20M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2017-12-31 | $19.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $19.44M derived: sum of 2 quarters · filed 2020-02-28 | $110.27M derived: sum of 3 quarters · filed 2020-02-28 | $113.95M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | -$12.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $90.82M derived: sum of 2 quarters · filed 2018-11-02 | $94.49M 10-Q · filed 2018-11-02 | $95.64M derived: sum of 4 quarters · filed 2019-03-06 | ||
| 2017-06-30 | $90.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $94.50M 10-Q · filed 2018-08-09 | $95.66M derived: sum of 3 quarters · filed 2019-03-06 | $95.55M derived: sum of 4 quarters · filed 2019-03-06 | ||
| 2017-03-31 | $3.67M 10-Q · filed 2018-05-03 | $4.83M derived: sum of 2 quarters · filed 2019-03-06 | $4.72M derived: sum of 3 quarters · filed 2019-03-06 | |||
| 2016-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $1.05M derived: sum of 2 quarters · filed 2019-03-06 | $23.67M 10-K · filed 2019-03-06 | |||
| 2016-09-30 | -$105.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $22.52M 10-Q · filed 2017-11-08 | ||||
| 2016-06-30 | $22.63M 10-Q · filed 2017-08-03 | |||||
| 2015-12-31 | $114.12K 10-K · filed 2018-03-06 | |||||
| 2014-03-31 | $57.26M 10-Q · filed 2014-05-09 | $120.05M 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |